News

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
Novo Nordisk Q1 earnings. Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% ...